Academic Journal
Q2Experimental and Clinical Psychopharmacology
About Experimental and Clinical Psychopharmacology
About Experimental and Clinical Psychopharmacology
Experimental and Clinical Psychopharmacology is a peer-reviewed scholarly journal published by 49 (United States). It focuses on Q2. Publication coverage spans 1993-2026.
Key indicators: ISSN 1936-2293, 1064-1297; H-index 105.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (105): Exceptionally high — 105 articles have each been cited at least 105 times. This indicates deep, sustained influence in the field.
Publishing in Experimental and Clinical Psychopharmacology
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Experimental and Clinical Psychopharmacology?
1936-2293, 1064-1297.
Who publishes Experimental and Clinical Psychopharmacology?
49.
What are Experimental and Clinical Psychopharmacology's metrics?
H-index 105.
Is Experimental and Clinical Psychopharmacology peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Substance Abuse Treatment and Outcomes; Neurotransmitter Receptor Influence on Behavior; Behavioral Health and Interventions; Smoking Behavior and Cessation; Mental Health Research Topics; Attention Deficit Hyperactivity Disorder.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Cannabis cues, motives, and attention enhancement: A cannabis priming pilot study.
Danielle S. Lowden, Frances Pearce, Charlie Drinkwater, Seth C. Harty et al.
2026-10 · DOI: 10.1037/pha0000859Tri-use of alcohol, cannabis, and nicotine in daily life among young adults: A day-level comparison of substance use outcomes to dual-use and alcohol-only use occasions.
Ashley N. Linden-Carmichael, Jennifer L. Shipley, Anna L. Sherman, Amy L. Stamates et al.
2026-10 · DOI: 10.1037/pha0000854Gimmie the Gummies: Initial validation of the Edibles Marijuana Purchase Task.
Elizabeth R. Aston, Michael Amlung
2026-10 · DOI: 10.1037/pha0000863An evaluation of N-acetylcysteine in a sequential oxycodone and cocaine rat self-administration model.
Christa Corley, Kathleen R. McNealy, Ashley M. White, Haley McManus et al.
2026-10 · DOI: 10.1037/pha0000855Feasibility data from a novel laboratory model of spontaneous opioid withdrawal.
Dhathri Srungaram, Natalia Rincon, Caitlyn J. Durgin, Kelly E. Dunn et al.
2026-10 · DOI: 10.1037/pha0000850Remotely delivered episodic future thinking and contingency management for smoking cessation: A randomized feasibility trial among military veterans in the United States.
Anthony N. Nist, Rafaela M. Fontes, Allison N. Tegge, Roberta Freitas-Lemos et al.
2026-10 · DOI: 10.1037/pha0000879Comparing current veterans affairs contingency management incentive structures against common alternatives on intentions to abstain from alcohol among veterans.
William Middleton, Mark Rzeszutek, Carolyn Lauckner, Sarah Iglehart et al.
2026-10 · DOI: 10.1037/pha0000867Neurobehavioral differences in value-based decision making between people with cocaine use disorder and controls.
Joshua A. Lile, Preston T. Tolbert, Thomas P. Shellenberg, William W. Stoops et al.
2026-10 · DOI: 10.1037/pha0000840Short-term lithium treatment modulates excitation/inhibition balance in resting-state electroencephalography (EEG) among survivors of medically severe suicide attempts.
Nicholas Murphy, Ynhi T. Thomas, Ioana Murgulet, Krisha Shah et al.
2026-10 · DOI: 10.1037/pha0000857E-cigarette puffs per day and changes in cigarettes per day among combustible cigarette smokers with opioid use disorder: A secondary analysis of the Electronic Cigarettes to Address Combustible Cigarette Smoking for People With opioid use disorder (ERASER) study.
Irene Pericot-Valverde, Deborah Kunkel, Justin Barron, Sarah Voss et al.
2026-10-01 · DOI: 10.1037/pha0000883Further adaptation of cross-commodity purchase task methodology: The impact of preference rank on demand.
Sarah C. Weinsztok, Derek D. Reed, Michael Amlung
2026-10 · DOI: 10.1037/pha0000872Effects of the neuroactive steroid precursor pregnenolone on stress- and alcohol cue–provoked pain responses in individuals with alcohol use disorder.
Riley Quinlan, Huaze Gao, Rajita Sinha, Verica Milivojevic et al.
2026-10 · DOI: 10.1037/pha0000862Associations among alcohol sensitivity, acquired tolerance, and drinking outcomes in late adolescence.
Jesus Chavarria, Jeffrey D. Wardell, Ryan P. Vetreno, Christian S. Hendershot et al.
2026-10-01 · DOI: 10.1037/pha0000881A 12-week study on the effects of betahistine (an H₃ antagonist/H₁ agonist) on cognitive functions in schizophrenia patients treated with olanzapine.
Hongyu Wang, Yongqian Wang, Weihao Huang, Wenshuang Yang et al.
2026-10 · DOI: 10.1037/pha0000858Acculturative stress and internalizing problems among Latinos who drink hazardously: The roles of distress tolerance and emotion dysregulation.
Emily L. Mallin, Karina Silva, Dania Y. Amarneh, Mallory R. Cotton et al.
2026-10 · DOI: 10.1037/pha0000856Comparing the sensory effects of menthol and synthetic coolants in e-liquids: A pilot investigation.
Danielle R. Davis, Wei Li, Ran Wu, Ralitza Gueorguieva et al.
2026-10 · DOI: 10.1037/pha0000865Identifying significant environmental predictors of change in delay discounting among adolescents in the Adolescent Brain Cognitive Development Study.
Geoffrey Kahn, Nadia Bounoua, Justin C. Strickland, I-Tzu Hung et al.
2026-10 · DOI: 10.1037/pha0000851An evaluation of e-cigarette use as it relates to alcohol demand among young adult college students.
Sydney R. Batchelder, Grant L. Saba, Ryan P. Papero
2026-10 · DOI: 10.1037/pha0000860Effects of simulated and real opioid withdrawal on delay discounting for opioids and money in people who use fentanyl daily.
Thomas P. Shellenberg, Tavishi Baidwan, Alexandra N. Johansen, Justin C. Strickland et al.
2026-09-28 · DOI: 10.1037/pha0000878Supplemental Material for Effects of Simulated and Real Opioid Withdrawal on Delay Discounting for Opioids and Money in People Who Use Fentanyl Daily
2026-09-24 · DOI: 10.1037/pha0000878.suppReviews
Community Reviews
Version History
October 9, 2026 at 10:24 pm
October 2, 2026